OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Products & Pricing
      • Banner Advertising Plans
      • eNewsletter Packages
      • Pre-Roll Advertising
      • Create A Deep Dive Conversation
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • How To Self Record An Interview and Presentations
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process
  • Publisher Calendar

  • Mobile
  • Connect Mobile App

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5594
  • Acute Myelogenous Leukemia 226
  • Bladder 96
  • Bone Metastases 5
  • Brain 79
  • Breast 548
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 209
  • Chronic Myelogenous Leukemia 54
  • Colorectal 172
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 177
  • General 341
  • Genitourinary 3
  • Head and Neck 110
  • Help 3
  • Hematologic Malignancies 206
  • Hodgkin Lymphoma 34
  • Imaging 2
  • Immunotherapy 179
  • Kidney 392
  • Liver 40
  • Lung 95
  • Lymphoma 235
  • Melanoma and Skin 107
  • Multiple Myeloma 535
  • Myeloproliferative Disease 37
  • News 149
  • Non-Hodgkin Lymphoma 81
  • Non-Small Cell Lung Cancer 554
  • Other 517
  • Ovarian 65
  • Pancreatic 102
  • Patient Resources 51
  • Pediatric 7
  • Prostate 300
  • Sarcoma 13
  • Sickle Cell 22
  • Small Cell Lung Cancer 81
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Bladder
  • Bone Metastases
  • Brain
  • Breast
  • Business Management
  • Cervical
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Colorectal
  • Conference Coverage
  • COVID-19
  • Gastrointestinal
  • General
  • Genitourinary
  • Head and Neck
  • Help
  • Hematologic Malignancies
  • Hodgkin Lymphoma
  • Imaging
  • Immunotherapy
  • Kidney
  • Liver
  • Lung
  • Lymphoma
  • Melanoma and Skin
  • Multiple Myeloma
  • Myeloproliferative Disease
  • News
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Other
  • Ovarian
  • Pancreatic
  • Patient Resources
  • Pediatric
  • Prostate
  • Sarcoma
  • Sickle Cell
  • Small Cell Lung Cancer
  • Supportive Care
  • Testicular
  • Urology
  • Uterine
Podcast - Miranda Gogishvili, MD #HighTechnologyMedicalCenter #UniversityClinic #ESMO21 #NonSmallCellLungCancer #NSCLC #Cancer #Research Abstract - LBA51 - EMPOWER-Lung 3 Study
0:06:04

Podcast - Miranda Gogishvili, MD #HighTechnologyMedicalCe...

Miranda Gogishvili, MD High Technology Medical Center, University Clinic speaks about ESMO 2021 Abstract - LBA51 - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC).

Link to Abstract:
https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/empower-lung-3-cemiplimab-in-combination-with-platinum-doublet-chemotherapy-for-first-line-1l-treatment-of-advanced-non-small-cell-lung-cancer

Abstract LBA51

Background:

EMPOWER-Lung 3 is a two-part, randomized Phase 3 trial of 1L therapy in patients with advanced (Stage III/IV) squamous (SQ) or non-squamous (NSQ) NSCLC who do not have actionable mutations (NCT03409614). The study's double-blind Part 2 enrolled patients regardless of their PD-L1 levels and compared the clinical activity and safety of cemiplimab, an anti-PD-1, plus (+) platinum-based chemotherapy to (vs) placebo (PBO)+chemo.

Methods:

Pts were randomly randomized (2:1; stratified by histology and PD-L1 expression) to receive cemiplimab 350 mg Q3W or PBO Q3W for 108 weeks (or until progression), plus up to four chemo cycles (followed by mandatory pemetrexed maintenance for NSQ pts assigned to a pemetrexed-containing regimen). Overall survival was the primary outcome (OS). Per blinded independent central review, key secondary objectives include progression-free survival (PFS) and objective response rate (ORR). Part 2 of the pre-specified 2nd interim analysis is shown here. The deadline for submitting data was June 14, 2021.

Results:

Overall, 466 patients were screened and assigned to one of two groups: cemiplimab+chemo (n=312) or PBO+chemo (n=154). The median (range) age of the participants was 63.0 (25-84) years, with 57.1 percent having NSQ NSCLC and 85.2 percent having Stage IV illness. With cemiplimab+chemo, the median OS was 21.9 months compared to 13.0 months with PBO+chemo (HR, 0.71; P=0.014). Compared to PBO+chemo, cemiplimab+chemo had a better median PFS (8.2 vs 5.0 months; HR, 0.56), a greater ORR (43.3 vs 22.7 percent), and a longer median duration of response (DOR) (15.6 vs 7.3 months) (Table). Grade 3 adverse events occurred 43.6 percent of the time in the cemiplimab+chemo arm and 31.4 percent of the time in the PBO+chemo arm.

Conclusions:

In patients with advanced NSCLC, 1L cemiplimab with chemo improved OS, PFS, ORR, and DOR compared to chemo alone, with a safety profile similar to cemiplimab monotherapy and platinum-based chemo.

Clinical trial identification
NCT03409614.

20 Views
1 year Ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Non-Small Cell Lung Cancer

Pembrolizumab's approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack West MD
0:09:13
Pembrolizumab's approval in this setting does not mean cl...
47 Views
1 month Ago
Jack West
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembrolizumab's approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack West MD
Pembrolizumab's approval in this setting does not mean cl...
273 Views
1 month Ago
Jack West
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Pembrolizumab's approval in this setting does not mean clinical value for Adjuvant Therapy for Resected NSCLC Jack West MD
0:10:09
Pembrolizumab's approval in this setting does not mean cl...
350 Views
1 month Ago
Jack West
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Side Effects of ROS1-TKIs - 2022 Program: Targeted Therapies Forum
0:04:09
Side Effects of ROS1-TKIs - 2022 Program: Targeted Therap...
6 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Side Effects of ALK-TKIs - 2022 Program: Targeted Therapies Forum
0:05:40
Side Effects of ALK-TKIs - 2022 Program: Targeted Therapi...
1 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Side Effects of EGFR-TKIs: Pneumonitis and Cardiotoxicity - 2022 Program: Targeted Therapies Forum
0:02:41
Side Effects of EGFR-TKIs: Pneumonitis and Cardiotoxicity...
2 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Managing Side Effects of EGFR-TKIs: Stomatitis and Diarrhea - 2022 Program: Targeted Therapies Forum
0:03:20
Managing Side Effects of EGFR-TKIs: Stomatitis and Diarrh...
1 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Dermatologic Side Effects of EGFR-TKIs - 2022 Program: Targeted Therapies Forum
0:10:03
Dermatologic Side Effects of EGFR-TKIs - 2022 Program: Ta...
2 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Oligoprogression in EGFR Mutant NSCLC - 2022 Program:Targeted Therapies Forum
0:05:55
Oligoprogression in EGFR Mutant NSCLC - 2022 Program:Targ...
4 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Biomarker Testing for NSCLC:The Importance and the Disparities-2022 Program:Targeted Therapies Forum
0:03:47
Biomarker Testing for NSCLC:The Importance and the Dispar...
4 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Liquid Biopsies in NSCLC - 2022 Program: Targeted Therapies Forum - English
0:02:14
Liquid Biopsies in NSCLC - 2022 Program: Targeted Therapi...
2 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Advanced ALK+, RET+ and MET+ NSCLC - 2022 Program: Targeted Therapies Forum - English
0:03:19
Advanced ALK+, RET+ and MET+ NSCLC - 2022 Program: Target...
5 Views
2 months Ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

comments@oncologytube.com Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592